Skip Navigation


Annals of Oncology Advance Access originally published online on December 12, 2008
Annals of Oncology 2009 20(3):481-485; doi:10.1093/annonc/mdn667
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
20/3/481    most recent
mdn667v1
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Goekkurt, E.
Right arrow Articles by Stoehlmacher, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Goekkurt, E.
Right arrow Articles by Stoehlmacher, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the European Society for Medical Oncology. All rights reserved. For permissions, please email: journals.permissions@oxfordjournals.org

gastrointestinal tumors

Pharmacogenetic analyses of hematotoxicity in advanced gastric cancer patients receiving biweekly fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT): a translational study of the Arbeitsgemeinschaft Internistische Onkologie (AIO)

E. Goekkurt1, S.-E. Al-Batran2, U. Mogck1, C. Pauligk2, J. T. Hartmann3, M. Kramer1, E. Jaeger2, G. Ehninger1 and J. Stoehlmacher1,*

1 Department of Internal Medicine I, University Hospital Carl Gustav Carus, University of Dresden, Dresden
2 Department of Oncology and Hematology, Krankenhaus Nordwest, Frankfurt
3 Department of Medical Oncology, Hematology, Immunology, Rheumatology, Pneumology, Eberhard-Karls-University, Tuebingen, Germany

* Correspondence to: Dr J. Stoehlmacher, University Hospital Carl Gustav Carus, Department of Internal Medicine I, Fetscherstr. 74, 01307 Dresden, Germany. Tel: +49-351-458-2311; Fax: +49-351-449-210-630; E-mail: jan.stoehlmacher{at}uniklinikum-dresden.de

Background: Docetaxel-based chemotherapy regimens have demonstrated activity in advanced gastric cancer (AGC). However, a high rate of grade 3/4 hematotoxicity was reported with these regimens. Our purpose was to identify pharmacogenetic markers with potential to detect patients with increased risk to encounter severe hematotoxicity following treatment with 5-fluorouracil, leucovorin, oxaliplatin and docetaxel (FLOT).

Patients and methods: Polymorphisms of genes involved in DNA repair, drug transport and metabolism were determined in 50 AGC patients receiving FLOT within a phase II trial. DNA was extracted from peripheral blood. Genotyping was carried out using PCR-based techniques.

Results: Patients possessing TS-group A genotypes (2R/2R, 2R/3RC, 3RC/3RC) were at increased risk for grade 3/4 hematotoxicity compared with patients harboring a TS-group B genotype (2R/3RG, 3RC/3RG, 3RG/3RG). In all, 59% (20 of 34) of patients with TS-group A genotypes developed grade 3/4 hematotoxicity compared with 25% (4 of 16) of those having TS-group B genotypes (P = 0.035). Grade 3/4 neutropenia occurred in 53% (18 of 34) of TS-group A patients compared with 19% (3 of 16) in TS-group B patients (P = 0.032). Multivariate analyses identified TS-group A genotypes as significant predictors of grade 3/4 overall hematotoxicity {odds ratio (OR) 4.62 [95% confidence interval (CI) 1.22; 17.44], P = 0.024} and neutropenia [OR 5.74 (95% CI 1.03; 32.08), P = 0.047].

Conclusion: TS-promoter polymorphisms may be associated with hematotoxicity in AGC patients receiving FLOT.

Key words: advanced gastric cancer, docetaxel, 5-fluorouracil, hematotoxicity, oxaliplatin, polymorphism

Received for publication September 8, 2008. Revision received September 8, 2008. Accepted for publication September 9, 2008.


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.